secwatch.observer — SEC 8-K summary
======================================

Issuer:     Innoviva, Inc. (INVA)
CIK:        0001080014
Form:       8-K
Filed at:   2025-02-26T23:59:59+00:00
Accession:  0001104659-25-017461
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Innoviva Q4 GSK royalties $66M, IST sales up 47% YoY; ZEVTERA launch mid-2025
-----------------------------------------------------------------------------

- Q4 GSK royalties $66.0M; full year $255.6M vs $252.7M in 2023.
- U.S. net product sales $24.9M in Q4, full year $80.9M (+47% YoY).
- Acquired U.S. rights to ZEVTERA; launch expected mid-2025.
- Zoliflodacin NDA submission to FDA on track for early 2025.
- Cash and receivables $391.4M; net income $20.3M in Q4 ($0.32 EPS).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1080014/000110465925017461/0001104659-25-017461-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1080014/000110465925017461/tm257428d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-017461

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer